Congenital and acquired thrombotic risk factors in women using oral contraceptives: Clinical aspects

Clinical and Applied Thrombosis/Hemostasis

Volumn 6, Issue 3, 2000, Pages 162-168

  Mira, Yolanda ^a   Aznar, Justo ^a   Estellés, Amparo ^a   Vayá, Amparo ^a   Villa, Piedad ^a   Ferrando, Fernando ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Ischemic Stroke; Oral Contraceptives; Thrombosis; Thrombosis Risk Factors; Venous Thrombois

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; PROTEIN S; PROTHROMBIN;

ADULT; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; DISEASE PREDISPOSITION; FEMALE; GENE MUTATION; GENETIC DISORDER; HUMAN; ORAL CONTRACEPTION; PRIORITY JOURNAL; PROTEIN S DEFICIENCY; RISK FACTOR; THROMBOPHILIA; VEIN THROMBOSIS;

ADOLESCENT; ADULT; ANTITHROMBINS; BRAIN ISCHEMIA; CONTRACEPTIVES, ORAL; FEMALE; HUMANS; RISK FACTORS; THROMBOPHILIA; VENOUS THROMBOSIS;

EID: 0033836674     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602960000600308     Document Type: Article

References (62)

1. Oral contraceptives and venous thromboembolism: Finding in a large prospective study
2. Oral contraceptive use and the risk of myocardial infarction
3. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease
4. Venous thromboembolic disease and combined oral contraceptives: Results of international multicente case-control study
5. Risk of idiopathic cardiovascular death and non fatal venous thromboembolism in women using oral contraceptives with differing progestagen components
6. Ischemic stroke and combined oral contraceptives: Results of an international muticentre case control study
7. A reevaluation of the risk for venous thromboembolism with the use of oral contraceptives and hormone replacement therapy
8. Acute myocardial infarction and combined oral contraceptives: Results of an international multicentre case control study
9. The risk of venous thromboemlolic disease amongst german women using oral contraceptives: A database study
10. Oral contraceptives and venous thromboembolism: A case control study
11. Myocardial infarction in young women with special reference to oral contraceptive practice
12. Myocardial infarction in users of low dose oral contraceptives
13. Oral contraceptives and myocardial infarction: New evidence leaves unanswered questions
14. Stroke in users of low dose oral contraceptives
15. Oral contraceptives and risk of thromboembolic stroke: Results from the Transnational Study on Oral Contraceptives and Health of Young Women
16. Cerebral thrombosis and oral contraceptives. A case control study
17. Case control study of risk of cerebral sinus thrombosis in oral contraceptive users and in carriers of hereditary prothrombotic conditions. The cerebral venous sinus thrombosis study group
18. High risk of cerebral vein thrombosis in carriers of a prothrombin gene mutation and in users of oral contraceptives
19. Thromboembolic stroke in young women. A European case control study on oral contraceptives: Transnational Research Group on Oral Contraceptives and the Health of Young Women
20. Oral contraceptives and venous thromboembolic disease. The findings from database studies in the United Kingdom and Germany
21. Oral contraception and increased risk of cerebral ischemia or thrombosis
22. Haemorrhagic stroke, overall stroke risk, and combined oral contraceptives: Results of an international, muticentre, case-control study
23. Use of oral contraceptives, cigarette smoking, and risk of subarachnoid hemorrhage
24. Risk factors for subarachnoid hemorrhage: A systematic review
25. Clotting factors during oral contraception further report
26. Epidemiological study of the haemostatic and other effects of oral contraceptives
27. Venous thrombosis, oral contraceptives and high factor VIII levels
28. Effect of oral contraceptives on haemostasis variables
29. Haemostatic changes and the oral contraceptive pill
30. Blood coagulation and oral contraceptives. A critical review
31. Physiological cagulation inhibitors (protein S, protein C and antithrombin III) in severe preeclamptic states and in users of oral contraceptives
32. Thrombosis risk of women with hereditary antithrombin III, protein C and protein S deficiency taking oral contraceptive medication
33. Increased levels of activated factor VII and decrease plasma protein S activity and circulating thrombomodulin during use of oral contraceptives
34. Low dose combined oral contraceptive
35. New progestogens in oral contraception
36. Enhancement by factor V Leiden mutation of risk of deep vein thrombosis associated with oral contraceptives containing a third-generation progesterone
37. Oral contraceptives and venous thromboembolism
38. Risk of venous thromboembolism with third generation oral contraceptives: A review
39. Venous thromboembolism among new users of different oral contraceptives
40. Influence of modern low dose oral contraceptives on hemostasis
41. In low dose oral contraceptives containing 20μg or 30μg ethinylestradiol, gestodene is associated with a lower increase in coagulant factor VII than in desogestrel
42. Estrogen dose and progestogen type: Their effect on hemostatic changes in oral contraceptive users
43. Third generation oral contraceptives and heritable thrombophilia as risk factors of non fatal venous thromboembolism
44. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C. Prediction of a co-factor to activated protein C
45. A common genetic variant in the 3' untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and increase in venous thrombosis
46. Factor V Leiden and other coagulation factor mutations affecting thrombotic risk
47. The 20210A allele of the prothrombin gene is a common risk factor among swedish outpatients with verified deep venous thrombosis
48. Prevalence of the prothrombin gene variant (nt 20210A) in venous thrombosis and arterial disease
49. Increased risk of venous thrombosis in oral contraceptive users who are carriers of the factor V Leiden mutation
50. Resistance to activated protein C in healthy women taking oral contraceptives
51. Oral contraceptives enhance the risk of clinical manifestation of venous thrombosis at a young age in females homozygous for factor V Leiden
52. Prothrombin 20210A polymorphism and thrird generation oral contraceptives. A case report o coeliac axis thrombosis and splenic infarction
53. Resistance to activate protein C, highly prevalent amongst users of oral contraceptives with venous thromboembolism
54. Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis
55. Activation of heparin co-factor II by dermatan sulphate
56. Modified test for activate protein C resistance
57. A rapid screening method for the factor V Arg 506 Gln mutation
58. Risk of venous thrombosis in carriers of the prothrombin G20210A variant and its interaction with oral contraceptives
59. The anticoagulant potential of the protein C system in hereditary and acquired thrombophilia: Pathomechanisms and new tools for assessing it clinical relevance
60. Protein C deficiency in a controlled set of unselected outpatients: An infrequent but clear risk factor for venous thrombosis. Leiden Thrombophilia Study (LETS)
61. The risk of thromboembolism in asymptomatic patients with protein C and protein S deficiency: A prospective cohort study
62. The long-term clinical course of acute deep venous thrombosis